JP2017525704A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525704A5
JP2017525704A5 JP2017509739A JP2017509739A JP2017525704A5 JP 2017525704 A5 JP2017525704 A5 JP 2017525704A5 JP 2017509739 A JP2017509739 A JP 2017509739A JP 2017509739 A JP2017509739 A JP 2017509739A JP 2017525704 A5 JP2017525704 A5 JP 2017525704A5
Authority
JP
Japan
Prior art keywords
seq
chain
amino acid
acid sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017509739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525704A (ja
JP6742986B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/046173 external-priority patent/WO2016029061A1/en
Publication of JP2017525704A publication Critical patent/JP2017525704A/ja
Publication of JP2017525704A5 publication Critical patent/JP2017525704A5/ja
Application granted granted Critical
Publication of JP6742986B2 publication Critical patent/JP6742986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017509739A 2014-08-20 2015-08-20 第Ｘａ因子解毒剤の凍結乾燥製剤 Active JP6742986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462039809P 2014-08-20 2014-08-20
US62/039,809 2014-08-20
PCT/US2015/046173 WO2016029061A1 (en) 2014-08-20 2015-08-20 Lyophilized formulations for factor xa antidote

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019165981A Division JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤

Publications (3)

Publication Number Publication Date
JP2017525704A JP2017525704A (ja) 2017-09-07
JP2017525704A5 true JP2017525704A5 (https=) 2018-09-13
JP6742986B2 JP6742986B2 (ja) 2020-08-19

Family

ID=55351266

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017509739A Active JP6742986B2 (ja) 2014-08-20 2015-08-20 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2019165981A Withdrawn JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2021172975A Active JP7416549B2 (ja) 2014-08-20 2021-10-22 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2023146769A Pending JP2023158199A (ja) 2014-08-20 2023-09-11 第Ｘａ因子解毒剤の凍結乾燥製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019165981A Withdrawn JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2021172975A Active JP7416549B2 (ja) 2014-08-20 2021-10-22 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2023146769A Pending JP2023158199A (ja) 2014-08-20 2023-09-11 第Ｘａ因子解毒剤の凍結乾燥製剤

Country Status (14)

Country Link
US (6) US20160237420A1 (https=)
EP (2) EP3750556A1 (https=)
JP (4) JP6742986B2 (https=)
KR (3) KR20250150675A (https=)
CN (2) CN113171447B (https=)
AU (3) AU2015305413B2 (https=)
CA (1) CA2961739C (https=)
DK (1) DK3182993T3 (https=)
EA (2) EA036091B1 (https=)
ES (1) ES2814157T3 (https=)
IL (2) IL250413B (https=)
SG (1) SG11201701247RA (https=)
WO (1) WO2016029061A1 (https=)
ZA (1) ZA201701764B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3604510T3 (pl) * 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
KR20250150675A (ko) * 2014-08-20 2025-10-20 포톨라 파마슈티컬스, 인코포레이티드 인자 xa 해독제용 동결건조된 제형
CN108883160B (zh) * 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
JP6959268B2 (ja) 2016-06-17 2021-11-02 ポートラ ファーマシューティカルズ， インコーポレイテッド 第ｘａ因子誘導体の調製
WO2018213151A1 (en) * 2017-05-18 2018-11-22 Merck Sharp & Dohme Corp. Pharmaceutical formulation comprising incretin-insulin conjugates
CN112512480B (zh) * 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
CN110760479A (zh) * 2019-05-17 2020-02-07 上海交通大学医学院附属瑞金医院 靶向血小板表达的凝血因子Xa及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2151044A1 (en) 1992-12-15 1994-06-23 Terence K. Brunck Novel inhibitors for factor xa
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6586584B2 (en) * 2001-01-29 2003-07-01 Becton, Dickinson And Company Sequences and methods for detection of Hepatitis C virus
CA2512680A1 (en) * 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
NZ592533A (en) 2005-11-08 2012-08-31 Millennium Pharm Inc METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
US20110178019A1 (en) 2008-09-03 2011-07-21 Brita Rippner New protecting compositions for recombinantly produced factor viii
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PL3604510T3 (pl) * 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US20130165459A1 (en) * 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
AU2011244348B2 (en) * 2010-04-20 2015-02-12 Octapharma Ag New stabilizing agent for pharmaceutical proteins
US8987285B2 (en) * 2010-12-03 2015-03-24 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
US9683020B2 (en) * 2011-08-01 2017-06-20 Emory University VLPS containing ligands and methods related thereto
JP6514893B2 (ja) * 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
GB201310946D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Antidote
KR20250150675A (ko) * 2014-08-20 2025-10-20 포톨라 파마슈티컬스, 인코포레이티드 인자 xa 해독제용 동결건조된 제형

Similar Documents

Publication Publication Date Title
JP2017525704A5 (https=)
JP2017043632A5 (https=)
RU2011151286A (ru) Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств
JP2015231997A5 (https=)
JP5960990B2 (ja) 組み換え技術によって製造された第ｖｉｉｉ因子のための新規な保護組成物
JP2009540001A5 (https=)
CO2018011733A2 (es) Composición farmacéutica
RU2011127913A (ru) Составы, содержащие антитела
EA200870264A1 (ru) Композиция антител
JP2012515221A5 (https=)
JP2013079270A5 (https=)
JP2016520075A5 (https=)
JP2014514275A5 (https=)
PL186950B1 (pl) Stabilizowany, nie zawierający albuminy, liofilizowany preparat rFVIII
TWI285106B (en) Stable pharmaceutical composition containing factor VIII
RU2013128277A (ru) СТАБИЛЬНЫЕ ИММУНОГЕННЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Staphylococcus aureus
JP6516829B2 (ja) 第ｖｉｉｉ因子製剤
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
JP2017510585A5 (https=)
JP2002249441A (ja) 血液凝固第ｖｉｉ因子を活性化するプロテアーゼ又はそのプロ酵素の安定化された液体製剤
RU2012122793A (ru) Композиция, способ и набор для альфа-1 ингибитора протеазы
MX349837B (es) Composicion de transglutaminasa seca.
CN116747312A (zh) 一种疫苗冻干保护剂、制剂及制备方法
RU2021107534A (ru) Составы, содержащие антитела
CA2956412C (en) Factor viii formulation